USPATFULL

File Type

Full text

Features

Thesauri

National Patent Classification, Cooperative Patent Classification,
International Patent Classification

Alerts (SDIs)

Every update (twice a week), Weekly, or Monthly (Weekly is the default)

CAS Registry
Number® IdentifiersPage Images

STN® AnaVist™



Keep & Share




SLART




STN Easy®



Learning Database

Structures

RecordContent• Full text and current classifications for the original (first published) publications of U.S.
patents and applications issued by the U.S. Patent and Trademark Office since 1975
• Complete Chemical Abstracts indexing for one equivalent U.S. chemical patent may
also be included in a record• Legal status information for U.S. patents since 1980
• Patent Classifications: NCL, CPC, IPC• PatentPak® - specific PDF links and data (available to PatentPak subscribers only)

File SizeMore than 10.9 million records (04/2022)

Coverage••••

1975-present
Partial coverage of selected technologies 1971-1974
Defensive publications from 1976-present
U.S. applications from 2001-present

Updates••••

Twice a week
U.S. Patent Classifications – no longer updated
Cooperative Patent Classifications – updated weeklyInternational Patent Classifications – updated quarterly

Language

English

Database
Producer

U.S. Patent and Trademark Office
Office of Data Base Administration
Data Maintenance Division2011 Jefferson-Davis Highway, CP2-9C18
Arlington, VA 22202 USA

Sources

U.S. patents issued by the U.S. Patent and Trademark Office

User Aids• Online Helps (HELP DIRECTORY lists all help messages available)• STNGUIDE

April 2022

2
USPATFULL

Clusters

•
•
•
•
•
•
•
•
•
•
•
•
•
•

RelatedDatabases• USPAT2• USPATOLD

PricingEnter HELP COST at an arrow prompt (=>).

April 2022

AEROTECH
AGRICULTURE
ALLBIBAUTHORS
BIOSCIENCECASRNSCOMPUTERCONSTRUCTION
CORPSOURCEELECTRICAL
ENGINEERINGENVIRONMENTFUELSFULLTEXT• GEOSCIENCE• HANAVIST• HEALTH• MATERIALS• MEDICINE• METALS• NPS• PATENTS• PETROLEUM• PHARMACOLOGY• PHYSICS• PNTTEXT• POLYMERS• USPATALLSTN Database Clusters information (PDF).

3
USPATFULL

Search and Display Field Codes
Fields that allow left truncation are marked with an asterisk (*).
Search Field Name

SearchCode

Display
Codes

Search Examples

Basic Index * (contains single words fromthe title (TI), abstract (AB), claims(CLM), detailed description (DETD),
summary (SUMM), drawing description(DRWD), parent case data (PARN), andgovernment interest (GOVI) fields)

None (or /BI)S GROWTH REGUL?
S NAPHTHALENE?
S ?VECTOR?

AB, CLM,
DETD, DRWD,
GOVI, PARN,
SUMM, TI

Abstract *Accession Number

/AB
/AN

AB
AN

Applicant City (Corporate) (12)Applicant Country (Corporate) (12)Applicant Name (Corporate) (12)Applicant State (Corporate) (12)Application Country
Application Date (1)/USPA.CTY/USPA.CNY/USPA/USPA.ST/AC/AD

Application Number (2,11)/AP

Application Year (1)Art Unit (1)

/AY
/ARTU
(or /ART)
/RN
/CLM
/CC

S COBALT CATALYST?/AB
S 94:1112/AN
S 2001:100195/AN
S CAMBRIDGE/USPA.CTY
S ARGENTINA/USPA.CNY
S GENOMICS/USPAS OH/USPA.ST
S US/AC AND L1
S NOV 23 1998/AD
S 19981123/AD
S US1977-851992/AP
S US2013-13261341/AP
S 1997/AY
S 126/ARTU
S 60-35-5/RN
S COBALT (S) SALT#/CLM
S 27/CCS HETEROCYCLIC/CCS ANIMAL GROWTH SUBSTANCES/CTS C12N0009/CPC
S 20121113/CPC.ACD

IT, RN
CLM
CC

S (B29C0066-71 (L)B29K2021-00)/CPC.CS
S (B29C0066-71 AND
B29K2021-00)/CPC.CS
S C04B0028-04/CPC (T)COMBINATION SET/CPC.KW
S C12N0009/CPC (S) I/CPC.KW

CPC.TABS 20130101/CPC.VER
S A61K0006-0014/CPCIS 19940111/DCD
S JAN 11 1994/DCD
S REISSUE/DT
S L1 AND ED>JAN 1, 2001
S SIEGEL ALAN M/EXNAM
S 564/EXF;S 564/48/EXF
S COBALT (S) MIXTURE/ECLM
S PARENT CASE DATA/FA
S PARN/FA
S GRANTED/FS or S APPLICATION/FS
S W-7405-ENG-48/GOVIS REACTION OF/IT
S 61895-14-5P/ITS BENTLEY TERENCE J?/INS CRANBURY/IN.CTY
S JAPAN/IN.CNY
S NJ/IN.ST
S 43017/IN.ZIP

CPC.TABCPCIDCDCAS Registry Number (RN) (CAS data)
Claim Text *Classification Code (CAS data) (code andtext) (3)Controlled Term (CAS data)
Cooperative Patent Classification (4,10)
Cooperative Patent Classification, Action
Date
Cooperative Patent Classification,
Combination Sets

/CT
/CPC
/CPC.ACD/CPC.CS

Cooperative Patent Classification,
Keywords (10)Cooperative Patent Classification, Version
Cooperative Patent Initial Classification
Disclaimer Date (1)/CPC.KW

Document Type (code and text)
Entry Date (1)Examiner Name
Examiner's Field of Search
Exemplary Claim Text *Field Availability (code and text)/DT (or /TC)/ED
/EXNAM
/EXF
/ECLM
/FA

File Segment (code and text)
Government Interest
Index Term (CAS data)

/FS
/GOVI
/IT

Inventor
Inventor Address, City
Inventor Address, Country
Inventor Address, State
Inventor Address, ZIP code (1)/IN (or /AU)
/IN.CTY/IN.CNY/IN.ST/IN.ZIP/CPC.VER
/CPCI
/DCD

USPA
USPA
USPA
USPA
AI
AI
AI
AI
ARTU

CT, IT
CPC
CPC.TAB

CPC.TABDT
Not displayed
EXNAM
EXF
CLM, ECLM
Not displayed
FS
GOVI
IT
IN
IN, INA
IN, INA
IN, INA
IN, INA
April 2022

4
USPATFULL

Search and Display Field Codes (cont'd)
SearchCode

Search Field Name
International Patent Classification, Action Date
International Patent Classification, Keyword Terms
International Patent Classification, Main (4,5.9)/IPC.ACD/IPC.KW/ICMInternational Patent Classification, Main Group
Range-Searchable (1)International Patent Classification, Secondary(4,5,9)/MGR

International Patent Classification, Subgroup
Range-Searchable (1)International Patent Classification, Version(s) (1)Language (code and text)
Legal Representative (3)Line Count (1)National Patent Classification, Current, Main andSecondary (4,6)/SGR

National Patent Classification, Current, Main (4,6)/NCLM

National Patent Classification Current, Secondary
(4,6)

/NCLS

National Patent Classification, Issue, Main andSecondary (4,6)/INCL

National Patent Classification, Issue, Main (4,6)/INCLM

National Patent Classification, Issue, Secondary(4,6)/INCLS

Number of Claims (1)Other Source
Patent Assignee (3)Patent Assignee Address, City
Patent Assignee Address, Country
Patent Assignee Address, State
Patent Assignee Address, ZIP code (1)Patent Assignee Type
Patent Assignee, Original
Patent Country
Patent Kind (7)Patent Number (2)

/CLMN
/OS
/PA (or /CS)
/PA.CTY/PA.CNY/PA.ST/PA.ZIP
/PAT
/PAO
/PC
/PK
/PN

Patent Number/Kind CodePriority Country
Priority Date (1)

PNK
/PRC
/PRD

Priority Number (2,8,11)/PRN

April 2022

/ICS

/IPC.VER/LA/LREP (or /AG)
/LN.CNT/NCL

Search Examples

DisplayCodes

S 20010529/IPC.ACD
S INITIAL/IPC.KW
S C07D/ICM
S C07D-209/ICM
S C07D-209-34/ICM
S C07C-125/06/ICM
S A01B001-00-A01B003-00/ICM
S ENZYMES/ICM
S 200-209/MGR

IPC
IPC
ICM

S C07C125/ICS
S A01B001/00-A01B003/00/ICS
S ENZYMES/ICS
S 400-600/SGR

ICS

S 7/IPC.VER
S L1 AND EN/LA
S JACKSON H G/LREP
S 1000-1500/LN.CNT
S 106035000/NCL
S 106/035.000/NCL
S 106/35/NCL
S ZEOLITES+NT/NCL
S 423308000/NCLM
S 423/NCLM
S ZEOLITES+NT/NCLM
S 106038000/NCLS
S 106/NCLSS ZEOLITES+NT/NCLS
S 433228000/INCL
S 433/INCL
S 433/227-433/229/INCLS ZEOLITES+NT/INCLS 523118000/INCLM
S 523/INCLM
S ZEOLITES+NT/INCLM
S 106035000/INCLSS 106/INCLSS ZEOLITES+NT/INCLSS CLMN>20
S 99:9994/OS
S AMERICAN CYANAMID/PA
S STAMFORD/PA.CTY
S UNITED KINGDOM/PA.CNY
S CT/PA.ST
S 53201/PA.ZIPS U S CORPORATION/PATS ABBOTT/PAO
S US/PC AND L2
S USA1/PK
S US5933861/PN
S US2001008908/PN
S US20050136407/PNK
S DE/PRC
S 19981213/PRD
S PRD>=DEC 13 1998
S DE1990-4041295/PRN
S US2013-61686038/PRN
S US2013-686038P/PRN

IPC
LA
LREP
LN.CNT
NCL

ICM

IPC

NCLM

NCLS

INCL

INCLM

INCLS

CLMN
OS
PA
PA
PA
PA
PA
PAT
PAO, RAI
PI
PI
PI
PNK
PRAI
PRAI
PRAI

5
USPATFULL

Search and Display Field Codes (cont'd)
Search Field Name

SearchCodePriority Year (1)Publication Date (1)Publication Year (1)Reassignment Agent
Reassignment Company
Reassignment Country
Reassignment Date (1)Reassignment Recorded Year (1)Reassignment Execution Date (1)Reassignment Execution Year (1)Reassignment Kind
Reassignment Update Date (1)Reference Non-Patent Information

/PRY
/PD
/PY
/RAA
/RAC
/RAC.CNY
/RAD
/RARY
/RAXD
/RAXY
/RAK
/RAUP
/REN

Reference Patent Classification (4,6)
Reference Patent Country
Reference Patent Inventor
Reference Patent IPC

/RPCL
/RPC
/RPIN
/RPIC

Reference Patent Number (2)Reference Patent Publication Date (1)Reference Patent Publication Year (1)Related Application Country
Related Application Date (1)Related Application Number (2,11)

/RPN
/RPD
/RPY
/RLC
/RLD
/RLN

Related Application Type
Related Application Year (1)Related Patent Publication Date (1)Related Patent Number (2)Related Patent Publication Year (1)Related Publication Indicator
Section Cross-reference (CAS data) (3)

/RLT
/RLY
/RLPD
/RLPN
/RLPY
/RLP
/SX

Supplementary Term (CAS data)
Term of Patent (1)Title *
Update Date (1)Update Date of CA Indexing (1)/ST/PTERM
/TI
/UP
/UPCA

Display
Codes

Search Examples
S PRY>=1997
S JUNE 1 1999/PD
S PY>=1998
S BAKER BOTTS/RAAS ABBOTT/RAC
S AUSTRALIA/RAC.CNY
S 20070411/RAD
S 2010/RARY
S 20080324/RAXD
S 2011/RAXYS CABLE/RAK
S 20071004/RAUPS HOUSE/REN
S SYNTHE? REACTION#/REN
S 100003000/RPCLS L7 AND US/RPC
S ASATO/RPINS A01B/RPICS A01B069/RPICS A01B069-04/RPICS US5174198/RPN
S DEC 1992/RPD
S 1970/RPY
S US/RLCS 12 AUG 1976/RLDS US76-713768/RLN
S US2000-532918/RLN
S DIVISION OF/RLTS RLY<1976
S 2011/RLPD
S US13887504/RLPN
S 1973/RLPYS ABANDONED/RLP
S 14/CC,SXS PHARMACOLOGY/SXS GROWTH PROMOT?/ST
S 1-4/PTERM
S THIOPHEN?/TI
S L2 AND UP>NOV 1 2001
S UPCA>=20011106

PRAI
PI
PI
RAA, RAI
RAC, RAI
RAI
RAD, RAI
Not displayed
RAXD, RAI
Not displayed
RAK, RAI
RAUP, RAI
REN
REP
REP
REP
REP

REP
REP
REP
RLI
RLI
RLI
RLI
RLI
RLI
RLI
RLI
RLI
CC, SXST
PTERM
TI
Not displayed
Not displayed(1) Numeric search field that may be searched with numeric operators or ranges.
(2) Either STN format or Derwent format may be used.
(3) Search with implied (S) proximity is available in this field.
(4) An online thesaurus is available for this field.
(5) This field contains the classifications and catchwords for main classification subject headings and subheadings from the current (7th)edition of the WIPO International Patent Classifications (IPC) manual. To search the classifications from any of the specific editions(1-8) of the IPC manual, use the field code followed by the edition number, e.g., /IC2, ICM2, /ICS2 for the 2nd edition. Catchwords
are included only in the fields for the 7th, 6th, and 5th editions of the IPC manual.
(6) This field is range-searchable in Manual of Classification order. However, it is not a numeric field and may not be searched using
numeric operators.
(7) Available for patent documents published starting in 2001.
(8) U.S. provisional priority numbers are searched only with the P appended, e.g., US1999-121903P/PRN.
(9) These fields have not been populated since December 31, 2005 with the introduction of IPC Reform.
(10) When searching combinations of CPC and CPC.KW data, use (S) proximity operator.
(11) Application numbers for U.S. utility patents from series code 13 forward, design patents (series code 29) and provisional patentapplications (series code 60 and 61) may be searched either with or without their series code. Include the series code if known toensure precision. Note that provisional patent application numbers searched without their series codes must have a P appended tothe end of the number (e.g., US2013-686038P). Series code information is not available for U.S. patent application numbers withseries codes below 13.
(12) Available for selected patent documents usually from September 2012 or later.
April 2022

6
USPATFULL

Property Fields(1)In USPATFULL a numeric search for a specific set of physical properties (/PHP) is available within the Basic
Index fields (most notably TI, AB, CLM, DETD, and SUMM). The numeric values are not displayed as single
fields, but ARE instead highlighted within HIT, KWIC and ALL displays.
EXPAND in the /PHP field to find numeric properties of interest, or type HELP NPS at an arrow prompt while
in USPATFULL to see a list of all available numeric properties. The /PHP index contains a complete list ofcodes and related text for all physical properties available for numeric property searching in USPATFULL.

Field
Code

Property

Unit

SymbolAmount of substance
Bit Rate
Stored Information
CapacitanceCatalytic Activity
Current Density
Molarity, Molar
Concentration
Conductance
DecibelDegreeDensity (MassConcentration
Dose Equivalent
DosageDose
Viscosity, dynamic
Electric Charge

Mol
Bit/Second
Bit
Farad
Katal
Ampere/Square Meter
Mol/Liter

mol
bit/s
Bit
F
kat
A/m2
mol/L

S 10 /AOS
S 8000-10000/BIR
S BIT > 3 MEGABIT
S 1-10 MF/CAP
S 200-250 KAT/CATAS CDN>10 A/M**2
S UREA/BI (S) 8/CMOL

Siemens
DecibelDegreeKilogram/Cubic Meter

S
dB
°
kg/m³

S 1S-3/CON
S DB>50
S CYLINDER/BI (S) 45/DEG
S 5E-3-10E-3/DEN

SievertMilligram/Kilogram/Day
Milligram/Kilogram
Pascal * Second
Coulomb

Sv
mg/kg/day
mg/kg
Pa * sC

Electrical Conductivity

Siemens/Meter

S/mS ECO>800 S/M (15A) AQUEOUS

Electric Current

AmpereA

S 1-10/ELC

Electric Field

Volt/Meter

V/m

S 200/ELF

Energy

Joule

J

/ERE
(/ERES)/FOR/FRE (/F)/IU/KVElectrical Resistivity

Ohm * MeterS DROPLETS (10A) 40 JOULE 70 JOULE /ENES ERE>0.1

Force
Frequency
International Unit
Viscosity, kinematic

NewtonHertz
none
Square Meter/Second

N
Hz
IU
m2/s

S 50 N /FORS OSCILLAT?/BI (S) 1- 3/FRE
S IU>1000 (P) VITAMIN AS METHYLPOLYSILOXANES/BI (10A)
100-200 CST/KV/LEN(/SIZ)/LUME

Length, Size

Meter

m

S 1-4/LEN

Luminous Emittance,
IlluminanceLuminous Flux
Luminous Intensity
Mass
Mass to Charge Ratio
Magnetic Flux
Density
Mass Flow Rate

Lux

lx

S 10-50/LUME

Lumen
CandelaKilogram
none
Tesla

Lm
cd
kg
m/z
T

S LUMF>1000
S LUMI<4
S ALLOY/BI (30A) 1E-10-1E-5/M
S MCH=1
S MFD>102

Kilogram/Second

kg/s

S MFR<0.1

Magnetic Field
Strength

Ampere/Meter

A/m

S 50 A/M/MFST

/AOS
/BIR
/BIT
/CAP
/CATA
/CDN
/CMOL
/CON
/DB
/DEG
/DEN (/C)
/DEQ
/DOA
/DOS
/DV
/ECH
(/CHA)/ECO(/ECND)/ELC(/ECC)/ELF(/ECF)
/ENE

/LUMF
/LUMI
/M
/MCH
/MFD
(/MFS)/MFR(/MFL)/MFST

April 2022

Ohm * mSearch Examples

S 100/DEQ
S 10 MG/KG/DAY/DOAS DOS>0.8
S DV>5000
S 0.0001-0.001/ECH

7USPATFULL

Super Search Fields
Enter a super search code to execute a search in one or more fields that may contain the desired information.
Super search fields facilitate crossfile and multifile searching. EXPAND may not be used with super search
fields. Use EXPAND with the individual field codes instead.
Search Field Name

SearchCode

FieldsSearched

Search Examples

Display
Codes

Cooperative Patent Classification (1)/CPC/CPCI, /CPCR

S C12N0009/CPC

CPC, CPCI,
CPCR
IPC

International Patent Classifications(2,3)
International Patent Classification(Old IPC)
Application Number Group (1,4)/IPC/IPC.OLD/IC, /ICM, /ICS,/IPCI, /IPCR/IC, /ICM, /ICSS A01B/IPC
S A01B001/IPC
S A01?/IPC.OLD/APPS/AP, /PRN, /RLN

AI, PRAI, RLI

Patent Applicant/Assignee (5)Patent Country Group

/PASS
/PCS

Patent Number Group (1)/PATS/PA, /USPA/PC, /PC.
/RPC, /RPC
/PN, /RLPN, /RPNS US56-626454/APPSS 56US-0626454/APPSS US2013-13261341/APPSS US2013-261341/APPS
S GENOMICS/PASSS US/PCS AND L1
S US102601/PATSS US0102601/PATS

PI, REP, RLI

IPC

PA, USPA
PI, REP, RLI(1) Either STN format or Derwent format may be used.
(2) A thesaurus is available for this field.
(3) EXPAND and SELECT work with this field.
(4) Application numbers for U.S. utility patents from series code 13 forward, design patents (series code 29) and provisional patentapplications (series code 60 and 61) may be searched either with or without their series code. Include the series code if known toensure precision. Note that provisional patent application numbers searched without their series codes must have a P appended tothe end of the number (e.g., US2013-686038P). Series code information is not available for U.S. patent application numbers withseries codes below 13.
(5) The /PASS search code only searches the applicant/assignee name portion of the /PA and /USPA fields.

CPC (/CPC) Thesaurus
The Cooperative Patent Classification (CPC) is jointly developed and maintained by the European Patent
Office and the US Patent and Trademark Office. This thesaurus is available in the /CPC search field. All
relationship codes can be used with both the EXPAND and SEARCH commands.
Relationship CodeALL
AUTO (1)
BT
CODE
DEF
HIE
KT
MAX
NEXT
NEXT(n)NT
PREV
PREV(n)TI

Content
All usually required terms (BT, SELF, CODE, DEF)
Automatic relationship (BT, SELF, CODE, DEF)
Broader terms (BT, SELF)
Classification Code (SELF, CODE)
Definition (SELF, DEF)
Hierarchy terms (all broader and narrower terms) (BT, SELF,
DEF, NT)
Keyword terms (SELF, KT)
All associated terms
Next classification within the same class (SELF, NEXT)
Next n classification within the same class
Narrower terms
Previous Code within the same class (SELF, PREV)
Previous n classifications within the same class
Complete Title of SELF Term and Broader Terms (BT, SELF)

Search Examples
E C12M0001-00+ALL/CPC
E G01J003-443+AUTO/CPC
E G01J0003-443+BT/CPC
E CARTRIDGES+CODE/CPC
E B65G0045-16+DEF/CPC
E A01B0001-00+HIE/CPC
E LASER+KT/CPC
E G01J0003-44+MAX/CPC
E A01B0001-24+NEXT/CPC
E A01B0001-24+NEXT3/CPC
E G05B0001-04+NT/CPC
E G05B0019-00+PREV/CPC
E G05B0019-00+PREV2/CPC
E G05B0001-03+TI/CPC(1) Automatic Relationship is SET OFF. In case of SET REL ON the result of EXPAND or SEARCH without any relationship code is thesame as described for AUTO.

April 2022

8
USPATFULL

Thesaurus Fields
A thesaurus is present for the National Patent Classification fields (/INCL, /INCLM, /INCLS, /NCL, /NCLM,/NCLS, /RPCL) and the International Patent Classification fields. The classifications and catchwords for themain headings and subheadings from the 7th edition of the WIPO International Patent Classification (IPC)
manual are available in the following fields: /IC, /ICM, /ICS, /IPCI, and /IPCR. The classifications from theprevious editions (1-7) are also available as separate thesauri. To EXPAND and SEARCH in the thesauri foreditions 1-8, use the field code followed by the edition number, e.g., /IC2, /ICM2, /ICS2 for the 2nd edition.
Catchwords are included only in the thesauri for the 8th, 7th, 6th, and 5th editions.
CodeContent

ALL

All associated terms

AUTO (1)ED
HIE

Automatic Relationship (BT, SELF)
Validity Range
Hierarchy (Broader and Narrower Terms(all Broader and Narrower Terms)(BT, SELF, NT)
IPC Index Terms
Complete Title of the SELF Term

INDEX
TI
BT

NEXT

Broader Terms(BT, SELF)
Keyword Terms (2)(SELF, KT)
Narrower Terms(SELF, NT)
Next Classification

PREV

Previous Classification

BRO

Complete ClassRT

Related Terms

KT
NT

ExampleE 135100000+ALL/INCL
E A01N025-04+ALL/IPC
E A01N025-06/IC REL=ON
E A01B001-00+ED/IPC
E 523523000+HIE/NCL
E A01B001-06+HIE/IPC
E A01B001-00+INDEX/IPC
E 135+TI/NCLM
E A01B001-04+TI/IPC
E 135120400+BT/NCLS
E A01N029-12+BT/IPC
E ZEOLITES+KT/NCL
E 126001**1+NT/INCL
E A01N025-00+NT/IPC
E 135086000+NEXT15/INCL
E A01B001-20+NEXT3/ICS
E 523523000+PREV3/NCLS
E A01B001-20+PREV5/IPC
E 135019000+BRO5/INCL
E A01B001-20+BRO3/IPC
E A01B001-16+RT/IPC(1) AUTOMATIC relationship is SET OFF. If you SET RELATION ON, the result of EXPAND without any relationship code is the sameas described for AUTO.
(2) Keyword terms are the catchwords corresponding to the USPTO Manual of Classifications subject index headings and subheadings.

April 2022

9
USPATFULLDISPLAY and PRINT Formats
Any combination of formats may be used to display or print answers. Multiple codes must be separated by
spaces or commas, e.g., D L3 1-10 TI,AB or D L3 1-10 TI AB. The fields are displayed or printed in the orderrequested.
Hit-term highlighting is available in all fields except DRWN and ECL. Highlighting must be on when a
SEARCH is performed to use the FHITSTR, HIT, HITRN, HITSTR, KWIC, and OCC formats.
FormatAB
AI (AP) (1)AN (2)ARTU
CC (SX)
CLM
CLM(n) (3)
CLMN
CT (2)
CPC
CPCI
CPCR
DCD
DETD
DRWD
DRWN
DT (TC)ECLECLM (3)EXF (2)
EXNAM
FS (2)GOVI
ICM (2)
ICS (2)IN (AU)INA (3)
INCLM (2)INCLS (2)
IPC.F (3)IPCI (2,5)
IPCR (2)IT
LA (3)
LN.CNT
LREP (AG)MFN
MRN
NCLM (2)NCLS (2)OS
PA (CS)
PAA (3)PAO
PARN
PAT (3)
PI (PN) (1)PNK
PRAI (PRN) (1)PTERM

Content
Abstract
Application Information
Accession Number
Art Unit
Classification Code and Section cross-reference (CAS data)
Patent Claim Text
Patent Claim Text for Claim n
Number of Claims
Controlled Term (CAS data)
Cooperative Patent Classification
CPC Initial Classification
CPC Reclassification
Disclaimer Date
Detailed Description
Drawing Description
Number of Drawings
Document Type
Exemplary Claim Number
Exemplary Claim Text
Examiner's Field of Search
Examiner Name
File Segment
Government Interest
IPC, Main
IPC, Secondary
Inventor (includes INA)
Inventor Address
Issue Main National Patent Classification CodeIssue Secondary National Patent Classification Code
IPC, First Invention
IPC, Initial Classification
IPC, Reclassification
Index Term (CAS data)
LanguageLine Count
Legal Representative
Microfilm Frame Number of document at the U.S. Patent and Trademark
OfficeMicrofilm Reel Number of document at the USPTO
Current Main National Patent Classification CodeCurrent Secondary National Patent Classification CodeOther Source Chemical Abstracts
Patent Assignee (includes PAA and PAT)
Patent Assignee Address
Patent Assignee, Original
Parent Case Data
Patent Assignee Type
Patent Information
Patent Number/Kind CodePriority Information
Term of Patent

ExamplesD 1-3 ABD 4 9 AI
D AN
D L3 5-7 ARTU
D L3 CC 1-5
D CLM L8
D CLM(2)
D CLMN
D 4 CT
D CPC
D CPCI
D CPCR
D L3 6,8 DCD
D 1-4 DETD
D L9 DRWD 3-6
D DRWND DT 2,6-10
D 7 L3 ECL
D 1-5, 10 ECLM
D 1,5,8 EXF
D EXNAM 4-8,11
D FS
D 3,5,7 GOVI
D 5-6 L1 ICM
D L4 1-6 ICS
D IN
D L5 1-4 INA
D 2,5 INCLM
D L2 1-3 INCLS
D IPC.FD IPCID IPCR
D 1,5,10 IT
D LA
D LN.CNT
D 2 7 LREP
D MFN
D MRN
D 1-2 NCLM
D 1-5 NCLS
D OS
D 1-3 PA
D 4 9 PAA
D PAO
D L3 5-7 PARN
D L3 PAT 1-5
D PI L8D PNK
D PRAI
D 4 PTERM

April 2022

10
USPATFULLDISPLAY and PRINT Formats (cont'd)
RAA
RAC
RAD
RAK
RAXD
REN
REP (RPN)RLI (RLN) (1)RN (3)RNK (6)RNKM (6)ST
SUMM
TI (2)
USPA

Reassignment Agent
Reassignment Company
Reassignment Date
Reassignment Kind
Reassignment Execution Date
Reference Non-Patent Information
Reference Patent Information
Related Application Information
CAS Registry Number (CAS data)
Relevance Rank in single file
Relevance Rank in multifiles
Supplementary Terms (CAS data)
Summary of the Invention
Title
Applicant Name (Corporate)

D RAA
D RAC
D RAD
D RAK
D RAXD
D L3 6,8 REN
D 1-4 REPD L9 RLI 3-6
D RN 2,6-10
D RNK
D RNKM
D ST
D L5 1-4 SUMM
D 2,5 TID USPAABS
ALL (1)

AB
AN, TI, IN, USPA, PA, PI, AI, PTERM, DCD, RLI, PRAI, DT, FS, REP,
REN, EXNAM, LREP, CLMN, ECL, DRWN, AB, GOVI, PARN, SUMM,
DRWD, DETD, CLM, INCL (INCLM, INCLS), NCL (NCLM, NCLS), CPC(CPCI, CPCR), IPC (IPC.VER, ICM, ICS, IPCI, IPC), EXF, ARTU,PPAK(If PatentPak enabled)
AI, PRAI, RLI
AN, TI, IN, PA, USPA, PI, AI, PTERM, DCD, RLI, PRAI, DT, FS, EXNAM,
LREP, CLMN, ECL, DRWN, LN.CNT
AN, TI, IN, PA, USPA, PI, AI, PTERM, DCD, RLI, PRAI, DT, FS, EXNAM,
LREP, CLMN, ECL, DRWN, LN.CNT, PPAK (If PatentPak enabled)

D L3 1-5 ABS
D 3 ALL

OS, CC, ST, IT
Compressed bibliographic information
CPCI, CPCR for the basic patent and patent family members
CPC, CPC.KW, CPC.ACD, CPC.VER in tabular format
Deduplicated list of CPC codes for the patent family
ALL, delimited for postprocessing
ABS, with a text label
ALL, indented with text labels
BIB, indented with text labels
BPP, indented with text labels
International Patent Classifications (IPC.VER, ICM, ICS)
MAX, indented with text labels
Issue National Patent Classification Code (INCLM, INCLS)
INCL (INCLM, INCLS), NCL (NCLM, NCLS), CPC (CPCI, CPCR), IPC(IPC.VER, ICM, ICS, IPCI, IPC), EXF, ARTU, OS, CC, ST, IT
International Patent Classifications (IPC.VER, ICM, ICS, IPCI, IPCR)
IPC in Tabular Format
Unique IPC codes for a basic and equivalents
RAI, indented with text labels
SPP, indented with text labels
STD, indented with text labels
AN, TI, IN, USPA, PA, PI, AI, PTERM, DCD, RLI, PRAI, DT, FS, REP,
REN, EXNAM, LREP, CLMN, ECL, DRWN, AB, GOVI, PARN, SUMM,
DRWD, DETD, CLM, INCL (INCLM, INCLS), NCL (NCLM, NCLS), CPC(CPCI, CPCR), IPC (IPC.VER, ICM, ICS, IPCI, IPCR), EXF, ARTU, OS,
CC, ST, IT
Current National Patent Classification Code (NCLM, NCLS)
PI, REP, RLI
RAD, RAXD, RAUP, RAK, PAO, RAC, RAC.CNY, RAA, MRN, MFN
AN, TI, IN, USPA, PA, PI, AI, RLI, PRAI, DT, FS, LN.CNT
AN, TI, NCL (NCLM, NCLS), CPC (CPCI, CPCR), IPC (IPC.VER, ICM,
ICS, IPCI, IPCR) (random answer display, no answer)

D CAS 3 L2
D CBIB
D CPC
D CPC.TAB
D CPC.UNIQ
D 1-15 DALL
D 1-4 IABS
D IALL 2
D IBIB 4-10
D IBPP
D 1-4 L2 IPC
D IMAX 1
D 1,5 L4 INCL
D L2 IND 1-4

APPS (1)BIB (1)
BPP(1)CAS
CBIB
CPC
CPC.TAB
CPC.UNIQDALL (1)
IABS
IALL (1)
IBIB (1)
IBPP(1)
IC (2)IMAX (1)
INCL (2)IND
IPC (2,5)
IPC.TAB (2,5)
IPC.UNIQ
IRAI (PA.HIST)
ISPP
ISTD (1)
MAX (1)

NCL (2)
PATS (1)
RAI (LSUS)
SBIB (1)
SCAN (2,4)

April 2022

D APPS
D BIB
D BPP

D 1-4 L2 IPC
D IPC.TAB
D IPC.UNIQ
D IRAI 1, D PA.HISTD ISPPD ISTD 1,5
D MAX L1 1

D 6,12 L1 NCL
D PATS 1-3
D RAI, D LSUS
D SBIBD SCAN

11
USPATFULLDISPLAY and PRINT Formats (cont'd)FormatContent

ExamplesSPP(1)AN, TI, IN, USPA, PA, PI, AI, RLI, PRAI, DT, FS, LN.CNT, INCL
(INCLM, INCLS), NCL (NCLM, NCLS), CPC (CPCI, CPCR), IPC(IPC.VER, ICM, ICS, IPCI, IPCR), EXF, PPAK (If PatentPak
enabled)

D SPP

STD (1)

AN, TI, IN, USPA, PA, PI, AI, RLI, PRAI, DT, FS, LN.CNT, INCL
(INCLM, INCLS), NCL (NCLM, NCLS), CPC (CPCI, CPCR), IPC(IPC.VER, ICM, ICS, IPCI, IPCR), EXF (STD is the default)
AN, TI, INCL (INCLM, INCLS), NCL (NCLM, NCLS), CPC (CPCI,
CPCR), IPC (IPC.VER, ICM, ICS, IPCI, IPCR)

D STD 1, 8

Front page format for: PI, TI, IN, USPA, PA, PTERM, DCD, AI, RLI,
PRAI, IPC (IPC.VER, ICM, ICS, IPCI, IPCR), INCL (INCLM,
INCLS), NCL (NCLM, NCLS), CPC (CPCI, CPCR), EXF, REP,
REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB
Front page format for: PI, TI, IN, USPA, PA, PTERM, DCD, AI, RLI,
PRAI, IPC (IPC.VER, ICM, ICS, IPCI, IPCR), INCL (INCLM,
INCLS), NCL (NCLM, NCLS), CPC (CPCI, CPCR), REP, REN,
EXF, ARTU, EXNAM, LREP, CLMN, DRWN, AB, PARN, SUMM,
DRWD, DETD, CLM
Front page format for: PI, TI, IN, USPA, PA, PTERM, DCD, AI, RLI,
PRAI, REP, REN, EXNAM, LREP, CLMN, DRWN

D FP

HIT display of CPC code searchedFirst hit CAS Registry Number, its text modification, its CA index
name, and its structure diagram
Fields containing hit terms
Hit IPC
Hit PatentPak entry (based on chemical name or RN search)
Hit CAS Registry Number and its text modification
Hit CAS Registry Number, its text modification, its CA index name,and its structure diagram
Up to 20 words before and after hit terms (KeyWord-In-Context)
Number of occurrences of hit terms and fields in which they occur

D CPC.HIT or D HITCPCD CBIB FHITSTR

TRIAL (FREE) (2)FP (1)FPALL (1)FPBIB (1)

CPC.HIT (HITCPC)
FHITSTRHIT
HITIPC (IPC.HIT)HITPPAKHITRNHITSTRKWIC
OCC (2)

D TRIALD FPALL L10 1

D 1-10 FPBIB

D HIT
D HITIPC or D IPC.HITD STD IT HITPPAKD HITRND HITSTRD KWIC
D OCC(1) By default, patent numbers, application and priority numbers are displayed in STN format. To display them in Derwent format, enter
SET PATENT DERWENT at an arrow prompt. To reset display to STN format, enter SET PATENT STN.
(2) No online display fee for the format.
(3) Custom display only.
(4) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.
(5) IPCI-2 is a display label relating to the most recent publication of the patent document. It is part of the IPCI display field.
(6) The RNK and RNKM formats display only the hit term occurrence ranking for the record, with the following line:
RELEVANCE SCORE ##. RNK is for the single file environment, while RNKM is for the multifile environment.

Extended DISPLAY and PRINT formats
Use the extended display formats to display not only the publication from the USPATFULL file, i.e., theoriginal publication, but also the latest publication for the invention, if available, from the USPAT2 file.
Format
BIB.EX
CLM.EX
FP.EX
IBIB.EX
IMAX.EX

Content
BIB for the original plus
BIB for the latest publication
CLM for the original plus
CLM for the latest publication
FP for the original plus
FP for the latest publication
IBIB for the original plus
BIB for the latest publication
IMAX for the original plus

ExamplesD 1-5 BIB.EX
DIS L2 CLM.EX
D FP.EX 1D IBIB.EX 1-3 L5
D IMAX.EX 1
April 2022

12
USPATFULL
MAX.EX
STD.EX

April 2022

IMAX for the latest publication
MAX for the original plus
MAX for the latest publication
STD for the original plus
STD for the latest publication

DISPLAY L1 1 MAX.EX
D STD.EX L5 3, 6

13
USPATFULL

Full-Text Browsing
User Request

ExampleSystem Response

DISPLAY BROWSE=> DISPLAY BROWSEENTER (L1) OR L#:.
ENTER (DIS),ANSWERNUMBERS, OR END:

NOVICE version

D BRO=> D BRO L1
:
:1-3
:.
:4 HIT:TI TX:*KWICEXPERT version

Answer number(s)Answer number(s) and format
Format only
*Format
Forward n fields
Backward n fields
Search forward for a character string
Search backward for a character string
End DISPLAY BROWSE:F3:B1:S GROWTH REGUL:S:S- ALKANOIC ACID
:S:END=>

display answers 1, 2, and 3 in default format
display next answer in default format
display answer 4 in HIT format
display title and text of last answer displayedchange default to KWIC;
no answer displayed
move forward 3 fields
move backward 1 fieldsearch forward within record for 'growth regul'
repeat search forward for the current string
search backward within record for 'alkanoic acid.'
repeat search backward for the current string
exit DISPLAY BROWSE and return to => prompt

SELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).
Field Name
Abstract
Accession Number
Applicant City (Corporate)
Applicant Country (Corporate)
Applicant Name (Corporate)
Applicant State (Corporate)
Application Country
Application Date
Application Information
Application Number
Application Number Group
Application YearArt Unit
Author (Inventor)
CAS Registry Number (CAS data)
Citation
Classification Code (CAS data)
Controlled Term
CPC Classification
CPC, Initial
CPC, Reclassified

Field Code
AB
AN
USPA.CTY
USPA.CNY
USPA
USPA.ST
AC
AD
AI
AP
APPS
AY
ARTU
AU
RN
CIT
CC
CT
CPC
CPCI
CPCR

ANALYZE/
SELECT (1)

SORT

Y
Y
Y
Y
Y
Y
Y (2)
Y (2)
Y (2,3,4)
Y (2,3)
Y (2,3,5)
Y (2)
Y
Y (6)
Y (2)
Y (2,7)YY (2)Y (20)Y (21)Y (21)

N
N
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
N
N
Y
N
N
N
N
April 2022

14
USPATFULL

SELECT, ANALYZE, and SORT Fields (cont'd)
Field Name

Field CodeANALYZE/
SELECT (1)SORT

CPC Hit Display
CPC Codes Deduplicated for patent family
Corporate Source (Patent Assignee)
Current Main National Patent Classification CodeCurrent National Patent Classification Code, Main and Secondary
Current Secondary National Patent Classification Code
Detailed Description
Disclaimer Date
Document TypeDrawing Description
Examiner Name
Examiner's Field of Search
Exemplary Claim Text
Government Interest
Index Term (CAS data)
International Patent Classifications, All codes
International Patent Classifications, Main and Secondary
Inventor
Inventor Address
Inventor Address, City
Inventor Address, Country
Inventor Address, State
Inventor Address, ZIP Code
IPC First Invention
IPC, Main
IPC, Secondary
IPC Initial Classification
IPC Reclassification
Issue Main National Patent Classification CodeIssue National Patent Classification Code, Main and Secondary
Issue Secondary National Patent Classification
Language
Legal Representative

CPC.HIT (HITCPC)
CPC.UNIQ
CS
NCLM
NCL
NCLS
DETD
DCD
DT
DRWD
EXNAM
EXF
ECLM
GOVI
IT
IPC
IC
IN
INA
IN.CTY
IN.CNY
IN.ST
IN.ZIP
IPC.F
ICM
ICS
IPCI
IPCR
INCLM
INCL
INCLS
LA
LREP
AG
LN.CNT
CLMN
OCC
OS
OSPN
PARN
PA
PAA
PA.CTY
PA.CNY
PA.ST
PA.ZIP
PAT
PAO
CLM
PC
PCS
PD
PI
PK
PN
PATS
PNK

Y
Y
Y (8)
Y
Y
Y
Y (9)
Y
Y
Y (9))
Y
Y
Y
Y
Y (2)
Y (10)
Y
Y
N
Y
Y
Y
Y
Y (10)YY
Y (10)Y (10)YYYYYY (11)NNN
Y (2)Y (2,12)
Y (9)
Y
N
Y
Y
Y
Y
Y
Y
Y
Y (2)
Y (2,13)
Y (2)Y (2,3,14)
Y
Y (2,3)
Y (2,3,15)
Y

Y
Y
Y
Y
Y
N
N
Y
Y
N
Y
Y
N
N
N
N
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
N
Y
Y
N
Y
N
N
Y
Y
Y
N
N
N
Y
Y
Y
Y
Y
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y

Line Count
Number of Claims
Occurrence Count of Hit Terms
Other Source Chemical Abstracts
Other Source Patent Number
Parent Case Data
Patent Assignee
Patent Assignee Address
Patent Assignee Address, City
Patent Assignee Address, Country
Patent Assignee Address, State
Patent Assignee Address, ZIP CodePatent Assignee Type
Patent Assignee, Original
Patent Claim Text
Patent Country
Patent Country Group
Patent Date
Patent Information
Patent Kind
Patent Number
Patent Number Group
Patent Number/Kind Code

April 2022

15
USPATFULL

SELECT, ANALYZE, and SORT Fields (cont'd)
Field Name
Patent Year
Priority Country
Priority Date
Priority Information
Priority Number
Priority Year
Reassignment Agent
Reassignment Company
Reassignment Country
Reassignment Date
Reassignment Execution Date
Reassignment Kind
Reassignment Update Date
Reference Patent Classification
Reference Patent Country
Reference Patent Information
Reference Patent Inventor
Reference Patent IPC
Reference Patent Number
Reference Patent Publication Date
Reference Patent Publication Year
Related Application Country
Related Application Date
Related Application Information
Related Application Number
Related Application Type
Related Application Year
Related Patent Number
Related Patent Publication Year
Section Cross-reference (CAS data)
Summary of the Invention
Supplementary Term (CAS data)
Term of Patent
Title
Treatment Code

Field CodeANALYZE/
SELECT (1)

SORT

PY
PRC
PRD
PRAI
PRN
PRY
RAA
RAC
RAC.CNY
RAD
RAXD
RAK
RAUP
RPCL
RPC
REP
RPIN
RPIC
RPN
RPD
RPY
RLC
RLD
RLI
RLN
RLT
RLY
RLPN
RLPY
SX
SUMM
ST
PTERM
TI
TC

Y (2)
Y (2)
Y (2)
Y (2,3,16)
Y (2,3)
Y (2)
Y
Y
Y
Y
Y
Y
Y
Y (2)
Y (2)
Y (2,3,17)
Y (2)
Y (2,3)
Y (2,3)
Y (2)
Y (2)
Y (2)
Y
Y (3,18)
Y (3)
Y
Y
Y (3)
Y
Y
Y (9)
Y
N
Y (default)
Y (19)

Y
Y
Y
Y
Y
Y
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
Y
N
Y
N
N
Y
Y
Y

(1)

HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT
TI.
(2) SELECT HIT and ANALYZE HIT are not valid with this field.
(3) Enter SET PATENT DERWENT at an arrow prompt (=>) to SELECT or ANALYZE patent and application numbers in Derwent
format.
(4) Selects or analyzes the application number with /AP appended to the terms created by SELECT.
(5) Selects or analyzes AP, PRN, and RLN and appends /APPS to the terms created by SELECT.
(6) Appends /IN to the terms created by SELECT.
(7) Extracts patent number, publication year with a truncation symbol appended and with /RE appended to the terms created by
SELECT.
(8) Appends /PA to the terms created by SELECT.
(9) Appends /BI to the terms created by SELECT.
(10) Selects or analyzes all codes and appends /IPC to the terms created by SELECT.
(11) Appends /LREP to the term created by SELECT.
(12) Appends /PN to the terms created by SELECT.
(13) Selects or analyzes the PC and RPC and appends /PCS to the] terms created by SELECT.
(14) Selects or analyzes the PN and appends /PN to the terms created by SELECT.
(15) Selects or analyzes PN, RPN, RLPN and appends /PATS to the terms created by SELECT.
(16) Selects or analyzes the PRN and appends /PRN to the terms created by SELECT.
(17) Selects or analyzes the RPN and appends /RPN to the terms created by SELECT.
(18) Selects or analyzes the RLN and appends /RLN to the terms created by SELECT.
(19) Appends /DT to the terms created by SELECT.
(20) Select CPC selects all CPCI and CPCR classifications and appends /CPC as a field code.
(21) SELECT appends /CPC.

April 2022

16
USPATFULL

Sample Records
DISPLAY IMAXANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER:
2005:44303 USPATFULL Full-text
TITLE:
Treatment of bipolar disorders and associated symptoms
INVENTOR(S):Romano, Steven Joseph, New York, NY, UNITED STATES
Giller, Earl L., Madison, CT, UNITED STATESHarrigan, Edmund P., Old Lyme, CT, UNITED STATES
Seeger, Thomas F., Mystic, CT, UNITED STATESPATENT ASSIGNEE(S):
Pfizer Inc (U.S. corporation)

PATENT INFORMATION:APPLICATION INFO.:PRIORITY INFORMATION:
DOCUMENT TYPE:
FILE SEGMENT:LEGAL REPRESENTATIVE:

NUMBERKIND
DATE---------------- ------ -------US 20050038036
A1
20050217
US 2004-843915
A1
20040512(10)NUMBERDATE-------------------------US 2003-471450P
20030516 (60)
Utility
APPLICATIONPFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49,
NEW YORK, NY, 10017-5612

ASSIGNMENT HISTORY FOR US 20050038036<no data available>
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
ABSTRACT:13
1

The present invention relates to a method for treatments relating to bipolar
disorder in a mammal, including a human, the treatments including treatment of
rapid-cycling bipolar disorder, treatment of symptoms of bipolar disorderselected from the group consisting of acute mania and depression, treatment foreffecting mood stabilization; treatment for preventing relapse into bipolar
episodes, and for the treatment of suicidal thoughts and tendencies associatedwith bipolar disorder, comprising administering to said mammal an effective
amount of a compound of the formula I:##STR1##or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X,
and Y are as defined.
[0001] This application claims priority under 35 U.S.C. 119 of U.S. Provisional
60/471,450, filed May 16, 2003. The entire contents of the prior application
are incorporated herein by reference.
FIELD OF THE INVENTION[0002] The present invention relates to the treatment of bipolar disorder in a
mammal, including a human. More specifically, the present invention is directedto the treatment in a mammal, including a human, of rapid-cycling bipolar
disorder, and for the treatment of symptoms of bipolar disorder, such symptoms
selected from the group consisting of acute mania and depression. The present
invention is also directed to a treatment method for effecting moodstabilization in a person afflicted with bipolar disorder. The present
invention further relates to a method of preventing relapse into bipolar
episodes in a person afflicted with bipolar disorder. The present invention isfurther directed to the treating suicidal thoughts and tendencies in a person
afflicted with bipolar disorder. The present invention also relates to newtherapeutic uses for piperazinyl-heterocyclic compounds of the formula I, as
defined below, for example ziprasidone.

April 2022

17
USPATFULLBACKGROUND OF THE INVENTION[0003] The piperazinyl-heterocyclic compounds of formula I of this invention
are disclosed in U.S. Pat. Nos. 4,831,031 and 4,883,795, both of which areassigned in common with the present application. Certain treatments for suchcompounds are disclosed in U.S. Pat. Nos. 6,127,373, 6,245,766, and 6,387,904,
all of which are also assigned in common with the present application. The
patents listed in this paragraph are incorporated by reference in their
entireties into the present disclosure.
SUMMARY OF THE INVENTION[0004] The present invention relates to the use of piperazinyl-heterocyclic
compounds of the formula I, as defined below, in methods for the treatment of
bipolar disorder in a mammal, including a human. Specifically, the present
invention is directed to a method for the treatment in a mammal, including ahuman, of rapid-cycling bipolar disorder, a method for the treatment ofsymptoms of bipolar disorder, such symptoms selected from the group consistingof acute mania and depression; a method for a treatment that effects moodstabilization in a person afflicted with bipolar disorder; a method for atreatment that prevents relapse into bipolar episodes in a person afflictedwith bipolar disorder; a method for the treatment of suicidal thoughts andtendencies in a person afflicted with bipolar disorder; such treatments
comprising administering a pharmaceutically effective amount of a compound of
the formula I:##STR2##[0005] or a pharmaceutically acceptable acid addition salt thereof, wherein Ar
is benzoisothiazolyl or an oxide or dioxide thereof each optionally substituted
by one fluoro, chloro, trifluoromethyl, methoxy, cyano, nitro or naphthyl
optionally substituted by fluoro, chloro, trifluoromethyl, methoxy, cyano or
nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzothiazolyl;
benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl; indolyl;
indanyl optionally substituted by one or two fluoro, 3-indazolyl optionallysubstituted by 1-trifluoromethylphenyl; or phthalazinyl; n is 1 or 2; and X andY together with the phenyl to which they are attached form quinolyl;
2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl;
indazolyl; 2-hydroxyindazolyl; indolyl; spiro; oxindolyl optionally substituted
by one to three of (C.sub.1-C.sub.3) alkyl, or one of chloro, fluoro or phenyl,
said phenyl optionally substituted by one chloro or fluoro; benzoxazolyl;
2-aminobenzoxazolyl; benzoxazolonyl; 2-aminobenzoxazolinyl; benzothiazolonyl;
bezoimidazolonyl; or benzotriazolyl.
● ● ●[0021] The psychiatric disorders and conditions referred to herein are known tothose of skill in the art and are defined in art-recognized medical texts suchas the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
American Psychiatric Association, 1994 (DSM-IV), which is incorporated hereinby reference in its entirety.
DETAILED DESCRIPTION OF THE INVENTION[0022] The piperazinyl-heterocyclic compounds of formula I can be prepared by
one or more of the synthetic methods described and referred to in U.S. Pat.
Nos. 4,831,031 and 4,883,795. U.S. Pat. Nos. 4,831,031 and 4,883,795 areincorporated herein by reference in their entireties.
● ● ●[0032] When an active compound of this invention is to be used in a humansubject to treat psychiatric conditions whose manisfestations include
psychiatric symptoms or behavioral disturbance, the prescribing physician will
normally determine the daily dosage. Moreover, the dosage will vary according
to the age, weight and response of the individual patient as well as theseverity of the patient's symptoms. However, in most instances, an effective
amount for treating the psychiatric conditions described herein, will be adaily dosage in the range from about 0.5 to about 500 mg, more specifically
April 2022

18
USPATFULL
about 10 mg a day to about 200 mg a day, relatively more specifically about 20
mg a day to about 180 mg a day, relatively still more specifically about 30 mg
a day to about 170 mg a day, and relatively even more specifically from about
40 to about 160 mg a day, in single or divided doses, orally or parenterally.
In some instances it may be necessary to use dosages outside these limits. The
receptor binding and neurotransmitter uptake inhibition profile for
Ziprasidone, 5-(2-(4-(1,2-benzisothiazol-3-yl)piperazinyl)ethyl)chlorooxindole,
was described in The Journal of Pharmacology and Experimental Therapeutics,
275, 101-113 (1995), which is incorporated herein by reference in its entirety.
A summary of its affinity for various receptors in the central nervous systemtissue is presented in Table 1.
TABLE 1
Ziprasidone
Receptor (Ligand)DA D1([.sup.3H]SCH23390)
6.28 + 0.17 (3)DA D2([.sup.3H]spiperone)
8.32 + 0.04 (6)DA D3([.sup.3H]raclopride) 8.14 + 0.03 (3)DA D4[.sup.3 H]spiperone)
7.49 + 0.11 (3)5-HT2A([.sup.3H]ketanserin) 9.38 + 0.03 (5)5-HT1A([.sup.3H]-80H-DPAT) 8.47 + 0.05 (4)5-HT-2C- ([.sup.3H]mesulergine) 8.88 + 0.05 (6)5-HT1D- ([.sup.3H]-5-HT)
8.69 + 0.04 (6)Alpha-1 ([.sup.3H]prazosin) 7.98 + 0.03 (3)Histamine H1
7.33 + 0.07 (3)([.sup.3H]mepyramine)
Neurotransmitter Reuptake
Blockade:
Norpinephrine
7.30 + 0.01 (4)5-HT
7.29 + 0.06 (3)DA
6.58 + 0.02 (3)[0033] The following examples illustrate methods of preparing various compounds
of formula I.
EXAMPLE 1[0034] 6-(2-(4-(1-Naphthyl)piperazinyl)ethyl)-benzoxazolone[0035] A. To a 500 ml three-necked round-bottomed flask equipped withmechanical stirrer and nitrogen inlet were added 200 grams of polyphosphoricacid, 13.51 grams (0.1 mole) of benzoxazolone, and 13.89 g (0.1 mole) of
bromoacetic acid. The reaction was heated with stirring at 115° C. for
2.5 hours and poured into 1 kg ice. The mixture was stirred mechanically for 1
hour to form a purple solid, which was then filtered off and washed with water.
The solid was slurried with acetone for 30 minutes, a small amount of purple
solid filtered off, and the brown filtrate evaporated. The resulting dark brown
gum was slurried with 150 ml ethanol for 30 minutes, and the brown solid
filtered off and washed with ethanol. This solid has a m.p. of
192°-194° C.
[0036] The solid (6.6 grams, 0.0257 mole) was placed in a 100 ml three-neckedround-bottomed flask equipped with magnetic stirrer, dropping funnel,
thermometer, and nitrogen inlet and 19.15 ml (0.257 mole) of trifluoroacetic
acid added. Triethylsilane (9.44 ml, 0.0591 mole) was added dropwise to thestirring slurry over 30 minutes. The reaction was stirred overnight at room
temperature, then poured into 150 grams ice. The mixture was stirred for 15
minutes, and the brown gum filtered off. The gum was dissolved in 100 ml ethyl
acetate, and 125 ml cyclohexane added, giving a brown precipitate, which wasfiltered and washed with cyclohexane. The filtrate was evaporated and theresulting yellow solid slurried with 50 ml isopropyl ether the pale yellow
solid was filtered off and dried to give 2.7 g 6-(2-bromoethyl)-benzoxazolone(11% yield for two steps), m.p. 148'-151° C.
[0037] B. To a 100 ml round-bottomed flask equipped with magnetic stirrer,
condenser, and nitrogen inlet were added 0.618 g (2.10 mmol) of
N-(1-naphthyl)piperazine 0.472 g (1.95 mmol) of 6-(2-bromoethyl)-benzoxazolone,
April 2022

19
USPATFULL
0.411 ml (2.92 mmol) of triethylamine, 50 ml ethanol, and a catalytic amount of
sodium iodide. The reaction was refluxed for 3 days, cooled, and evaporated toa brown gum. The gum was partitioned between 50 ml water and 75 ml methylene
chloride, the pH adjusted with aqueous 1 N sodium hydroxide solution, and alittle methanol added to facilitate phase separation. The methylene chloride
layer was dried over sodium sulfate and evaporated, then chromatographed on
silica gel. Fractions containing the product were combined and evaporated, theresidue taken up in ethyl acetate, treated with hydrochloride gas, and theresulting hydrochloride salt of the product filtered off to give the whilesolid title compound, m.p. 282°-285° C., 213 mg (23% yield).
EXAMPLE 2[0038] 6-(2-(4-(1-Naphthyl)piperazinyl)ethyl)-benzimidazolone● ● ●EXAMPLE 17[0100] 6-(4-(2-(3-Benzisothiazolyl)piperazinyl)ethyl)phenyl)benzothiazolone[0101] To a 100 ml round-bottomed flask equipped with condenser and nitrogen in
let were added 1.03 grams (4 mmol) 6-(2-bromoethyl)-benzothiazolone, 0.88 grams(4 mmol) N-benzisothiazolylpiperazine, 0.84 grams (8 mmol) sodium carbonate, 2
mg sodium iodide, and 40 ml methylisobutyl ketone. The reaction was refluxed 36
hours, cooled, filtered, and the filtrate evaporated. The residue waschromatographed on silica gel using ethyl acetate as eluent to afford an oil,which was taken up in methylene chloride and precipitated by addition of ether
saturated with HCl. The solid was filtered, washed with ether, dried briefly,
washed with a minimal amount of acetone and dried to afford a white solid, m.p.
288°-290° C., 1.44 grams (76.7%).
EXAMPLE A[0102] A. Following the general procedure for the preparation of
5-(chloroacetyl)oxindole in Example 12A, the following intermediates wereprepared from the appropriate oxindoles:[0103] 5-(chloroacetyl)-1-ethyl-oxindole (81%, m.p. 1570-1590 C.,
NMR(CDCl.sub.3); 1.30(t,3H), 3.60(s,2H), 3.85(q,2H), 4.70(s,2H),
6.85-8.15(m,2H);[0104] 5-(chloroacetyl)-1-methyloxindole(C.sub.1, H.sub.10ClNO.sub.2, 92%, m.p.
2010-2020 C.;[0105] 1(3-chlorophenyl)-5(chloroacetyl)oxindole, 98% m.p.
143°-145° C., NMR(DMSO-d.sub.6): 3.85(br s,2H), 5.10(s,2H),
6.8(d,1H), 7.4-7.6(m,4H), 7.9 (s+d,2H); MS(%): 319(17, 270(100), 179(46),
178(38);[0106] 1,3-dimethyl-5-(chloroacetyl)oxindole, 97% m.p. 206°-207°[0107] 5-(chloroacetyl)-spirocyclopentane[1,3']-indolone, 99%, m.p.
203°-204° C.(dec).; NMR(DMSO-d.sub.6): 2.0(brs,8H), 4.95(s,2H),
6.9(d,1H), 7.8(d+s,2H), 10.6(brs, 1H);
[0108] 5-(chloroacetyl)-1,3,3-trimethyloxindole, 82%, m.p. 1820-185° C.,
NMR(CDCl.sub.3): 1.45(s,6H), 3.25(s,3H), 4.65(s,2H), 6.9(d, 1H), 7.9(s,1H),8.0(d,1H);[0109] 6-fluoro-5-(chloroacetyl)oxindole, 96%, m.p. 1780-1800 C.;
NMR(DMSO-d.sub.6): 3.5(s,2H), 4.8(d,2H), 6.7-7.2(m,2H), 7.8(d,1H);[0110] 7-fluoro5-(chloroacetyl)oxindole, 91%, m.p. 1940-1960 C.,
NMR(DMSO-d.sub.6): 3.68(s,2H), 5.13(s,2H) 7.65-7.9(dd,2H);[0111] 6-chloro-5-(chloroacetyl)oxindole, 99%, m.p. 206°-207° C.;
April 2022

20
USPATFULL[0112] 5-(chloroacetyl)-3,3-dimethyl-6-fluorooxindole, 89%, m.p.
185°-1880 C.;[0113] 5-(y-chlorobutyryl)oxindole, 84%, oil, MS(%): 239, 237(55);[0114] 1-ethyl-5-(y-chlorobutyryl)oxindole, 99%, oil, NMR(CDCl.sub.3):
1.2(t,3H), 1.5-2.7(m,5H), 3.0-3.2(m,2H), 3.5-4.0(m,3H), 6.8-7.0(d,1H),
7.9(s,1H), 7.95(d,1H), and[0115] 5-(y-chlorobutyryl)-7-fluorooxindole, 53%, m.p. 156°-160°
C.
EXAMPLE B[0116] By the same procedure as that used to prepare 5-(2-chlorethyl)oxindole
in Example 12B, the following were prepared:[0117] 5-(2-chloroethyl)-1-ethyloxindole, 93%, m.p. 120°-122° C.;
NMR (CDCl.sub.3): 1.30(t,2H), 3.55(s,2H), 3.65-4.0(m,4H), 6.8-7.3(m,3H);[0118] 5-(2-chloroethyl)-1-methyloxindole, 99%, m.p. 127°-130°
C.; NMR (CDCl.sub.3): 3.1(t,2H), 3.2(s,2H), 3.5(s,2H), 3.75(t,2H), 6.8(d,1H),
7.15(s,1H), 7.3(d,1H);[0119] 5-(2-chloroethyl)-1-(3-chlorophenyl)oxindole, 83%, m.p.
75°-76° C.;[0120] 5-(2-chloroethyl)-1,3-dimethyloxindole, 58%, m.p. 73°-750 C., NMR
CDCl.sub.3): 1.45-1.55(d,3H), 3.03-3.2(t,2H), 3.25(s,3H), 3.30-3.60(q,1H),
3.65-3.90(t,2H), 6.85-6.90(d,1H), 7.15(s,1H), 7.15-7.30(d,1H);[0121] 5'-(2-chloroethyl)-spiro[cyclopentane-1,3'-indoline]-2'-one, 92%, m.p.
140°-142° C.; NMR(DMSO-d.sub.6): 2.8(brs,8H), 2.90(t,2H),
3.7(t,2H), 6.6-7.1(m,3H), 10.2(brs,1H);[0122] 5-(2-chloroethyl)-,3,3-trimethyloxindole, 83%, oil;[0123] 5-(2-chloroethyl)-6-fluorooxindole 62%, m.p. 1880-190° C.;
NMR(DMSO-ds) 3.05(t,2H), 3.5(2,2H), 3.85(t,2H), 6.6-7.3(m,2H);[0124] 5-(2-chloroethyl)-7-fluorooxindole, 79%, m.p. 176°-1790 C.;
MS(%); 213(50), 180(20), 164(100), 136(76);[0125] 5-(2-chloroethyl)-6-chlorooxindole, 94%, m.p. 210°-211°
C.;[0126] 5-(2-chloroethyl)-3,3-dimethyl-6-fluorooxindole (C.sub.12H.sub.13ClFNO,
84%, m.p. 195°-1960 C., NMR(DMSO-d.sub.6): 1.3(s,6H), 3.05(t,2H),
3.7(t,2H), 6.65(d,1H), 7.1(d,1H), 10.1(br s,1H);[0127] 5-(4-chlorobutyl)oxindole, 40%, oil, NMR(CDCl.sub.3): 1.6-2.0(m,4H),
2.6(m,2H), 3.6(m,4H), 6.8-7.15(m,3H), 9.05(br s, 1H);
[0128] 5-(4-chlorobutyl)-ethyloxindole, 48%, oil, NMR(CDCl.sub.3): 1.25(t,3H),
1.5-1.95(m,4H), 2.6(m,2H), 3.5(s,2H), 3.55(t,2H), 3.75(q,2H), 6.7-7.2(m,3H);
and[0129] 5-(4-chlorobutyl)-7-fluorooxindole, 71%, m.p. 1680-173° C.
What is claimed is:
1. A method for treating rapid-cycling bipolar disorder in a mammal in need
thereof comprising administering to said mammal a pharmaceutically effective
amount of a compound of formula##STR5## or a pharmaceutically acceptableacid addition salt thereof, wherein Ar is benzoisothiazolyl or an oxide or
dioxide thereof each optionally substituted by one fluoro, chloro,
April 2022

21
USPATFULL
trifluoromethyl, methoxy, cyano, nitro or naphthyl optionally substituted byfluoro, chloro, trifluoromethyl, methoxy, cyano or nitro; quinolyl;
6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzothiazolyl;
benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl; indolyl;
indanyl optionally substituted by one or two fluoro, 3-indazolyl optionallysubstituted by 1-trifluoromethylphenyl; or phthalazinyl; n is 1 or 2; and X
and Y together with the phenyl to which they are attached form quinolyl;
2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl;
indazolyl; 2-hydroxyindazolyl; indolyl; spiro; oxindolyl optionally substituted
by one to three of (C.sub.1-C.sub.3) alkyl, or one of chloro, fluoro or phenyl,
said phenyl optionally substituted by one chloro or fluoro; benzoxazolyl;
2-aminobenzoxazolyl; benzoxazolonyl; 2-aminobenzoxazolinyl; benzothiazolonyl;
bezoimidazolonyl; or benzotriazolyl.
2. A method of treating in a mammal in need thereof a symptom of bipolar
disorder selected from the group consisting of acute mania, depression, andsuicidal thoughts or suicidal tendencies, which method comprises administering
to said mammal a pharmaceutically effective amount of a compound of formula##STR6## or a pharmaceutically acceptable acid addition salt thereof, wherein
Ar is benzoisothiazolyl or an oxide or dioxide thereof each optionallysubstituted by one fluoro, chloro, trifluoromethyl, methoxy, cyano, nitro or
naphthyl optionally substituted by fluoro, chloro, trifluoromethyl, methoxy,
cyano or nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl;
benzothiazolyl; benzothiadiazolyl; benzotriazolyl; benzoxazolyl;
benzoxazolonyl; indolyl; indanyl optionally substituted by one or two fluoro,
3-indazolyl optionally substituted by 1-trifluoromethylphenyl; or phthalazinyl;
n is 1 or 2; and X and Y together with the phenyl to which they are attachedform quinolyl; 2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl;
benzoisothiazolyl; indazolyl; 2-hydroxyindazolyl; indolyl; spiro; oxindolyl
optionally substituted by one to three of (C.sub.1-C.sub.3) alkyl, or one ofchloro, fluoro or phenyl, said phenyl optionally substituted by one chloro or
fluoro; benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl;
2-aminobenzoxazolinyl; benzothiazolonyl; bezoimidazolonyl; or benzotriazolyl.
3. The method of claim 2 wherein the symptom is selected from the groupconsisting of acute mania and depression.
4. The method of claim 2 wherein the symptom is suicidal thoughts or
tendencies.
5. A method of stabilizing mood or of preventing relapse into a bipolar episodein a mammal afflicted with bipolar disorder, which method comprises
administering to said mammal a pharmaceutically effective amount of a compoundof formula##STR7## or a pharmaceutically acceptable acid addition salt
thereof, wherein Ar is benzoisothiazolyl or an oxide or dioxide thereof each
optionally substituted by one fluoro, chloro, trifluoromethyl, methoxy, cyano,nitro or naphthyl optionally substituted by fluoro, chloro, trifluoromethyl,
methoxy, cyano or nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl;
quinazolyl; benzothiazolyl; benzothiadiazolyl; benzotriazolyl; benzoxazolyl;
benzoxazolonyl; indolyl; indanyl optionally substituted by one or two fluoro,
3-indazolyl optionally substituted by 1-trifluoromethylphenyl; or phthalazinyl;
n is 1 or 2; and X and Y together with the phenyl to which they are attachedform quinolyl; 2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl;
benzoisothiazolyl; indazolyl; 2-hydroxyindazolyl; indolyl; spiro; oxindolyl
optionally substituted by one to three of (C.sub.1-C.sub.3) alkyl, or one ofchloro, fluoro or phenyl, said phenyl optionally substituted by one chloro or
fluoro; benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl;
2-aminobenzoxazolinyl; benzothiazolonyl; bezoimidazolonyl; or benzotriazolyl.
6. The method of claim 5, for stabilizing mood.
7. The method of claim 5, for preventing relapse into a bipolar episode.
8. The method of any preceding claim wherein the compound is ziprasidone.
9. The method of claim 1, 2, or 5 wherein the compound is ziprasidone and isadministered in dosages of about 0.5 mg to about 500 mg per day.
April 2022

22
USPATFULL
10. The method of claim 1, 2, or 5 wherein the compound is ziprasidone and theadministration is oral.
11. The method of claim 1, 2, or 5 wherein the compound is ziprasidone and theadministration is parenteral.
12. The method of claim 1, 2, or 5 wherein the treatments effect improvement in
the mammal within about 96 hours after administrating the compound.
13. The method of claim 1, 2, or 5 wherein the treatments effect improvement in
the mammal within about 24 to about 96 hours after administering the compound.
ISSUE U.S. PATENT CLASSIF.:
MAIN:
514/253.060
SECONDARY:
514/254.020; 514/254.060
CURRENT U.S. PATENT CLASSIF.:
MAIN:
514/253.060
SECONDARY:
514/254.020; 514/254.060
COOP. PATENT CLASSIF.:
INITIAL:
A61K0031-496 [I]INT. PATENT CLASSIF.:[7]
INITIAL:
A61K0031-496 [ICM,7]
RECLASS:
A61K0031-496 [I]; A61P0025-00 [I]; A61P0025-24 [I]
CHEMICAL ABSTRACTS INDEXING---------------------------COPYRIGHT 2013 ACS on STN

PATENTKIND
DATE---------------- ---- -------OS
CA 141:420463 * WO
2004100957 A1 20041125* CA Indexing for this record included
CA CLASSIF.:
1-11 (Pharmacology)
SUPPL. TERM:
bipolar disorder treatment piperazinyl heterocyclic compd;
ziprasidone treatment acute mania depression moodstabilization; suicide thought treatment ziprasidone
INDEX TERM:
Dopamine receptors(D1, ziprasidone affinity for, in central nervous systemtissue; treatment of bipolar disorders and associatedsymptoms using piperazinyl-heterocyclic compds., especiallyziprasidone)
INDEX TERM:
Dopamine receptors(D1A, ziprasidone affinity for, in central nervous
system tissue; treatment of bipolar disorders andassociated symptoms using piperazinyl-heterocyclic
compds., especially ziprasidone)● ● ●INDEX TERM:
50-67-9, 5-HT, biological studies
51-41-2, Norepinephrine
51-61-6, Dopamine, biological studies(ziprasidone blockade of reuptake of; treatment of
bipolar disorders and associated symptoms using
piperazinyl-heterocyclic compds., especially ziprasidone)

D CLM.EX-- Original Publication -CLM

(APPLICATION - A1)

What is claimed is:
1. A method for treating rapid-cycling bipolar disorder in a mammal inneed thereof comprising administering to said mammal a pharmaceuticallyeffective amount of a compound of formula##STR5## or apharmaceutically acceptable acid addition salt thereof, wherein Ar is
benzoisothiazolyl or an oxide or dioxide thereof each optionallysubstituted by one fluoro, chloro, trifluoromethyl, methoxy, cyano,nitro or naphthyl optionally substituted by fluoro, chloro,

April 2022

23
USPATFULL
trifluoromethyl, methoxy, cyano or nitro; quinolyl;
6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzothiazolyl;
benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl;
indolyl; indanyl optionally substituted by one or two fluoro,
3-indazolyl optionally substituted by 1-trifluoromethylphenyl; or
phthalazinyl; n is 1 or 2; and X and Y together with the phenyl towhich they are attached form quinolyl; 2-hydroxyquinolyl;
benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl; indazolyl;
2-hydroxyindazolyl; indolyl; spiro; oxindolyl optionally substituted by
one to three of (C.sub.1-C.sub.3) alkyl, or one of chloro, fluoro or
phenyl, said phenyl optionally substituted by one chloro or fluoro;
benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl;
2-aminobenzoxazolinyl; benzothiazolonyl; bezoimidazolonyl; or
benzotriazolyl.
2. A method of treating in a mammal in need thereof a symptom of bipolar
disorder selected from the group consisting of acute mania, depression,and suicidal thoughts or suicidal tendencies, which method comprises
administering to said mammal a pharmaceutically effective amount of acompound of formula##STR6## or a pharmaceutically acceptable acidaddition salt thereof, wherein Ar is benzoisothiazolyl or an oxide or
dioxide thereof each optionally substituted by one fluoro, chloro,
trifluoromethyl, methoxy, cyano, nitro or naphthyl optionallysubstituted by fluoro, chloro, trifluoromethyl, methoxy, cyano or nitro;quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzothiazolyl;
benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl;
indolyl; indanyl optionally substituted by one or two fluoro,
3-indazolyl optionally substituted by 1-trifluoromethylphenyl; or
phthalazinyl; n is 1 or 2; and X and Y together with the phenyl towhich they are attached form quinolyl; 2-hydroxyquinolyl;
benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl; indazolyl;
2-hydroxyindazolyl; indolyl; spiro; oxindolyl optionally substituted by
one to three of (C.sub.1-C.sub.3) alkyl, or one of chloro, fluoro or
phenyl, said phenyl optionally substituted by one chloro or fluoro;
benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl;
2-aminobenzoxazolinyl; benzothiazolonyl; bezoimidazolonyl; or
benzotriazolyl.
3. The method of claim 2 wherein the symptom is selected from the groupconsisting of acute mania and depression.
4. The method of claim 2 wherein the symptom is suicidal thoughts or
tendencies.
5. A method of stabilizing mood or of preventing relapse into a bipolar
episode in a mammal afflicted with bipolar disorder, which method
comprises administering to said mammal a pharmaceutically effective
amount of a compound of formula##STR7## or a pharmaceutically
acceptable acid addition salt thereof, wherein Ar is benzoisothiazolyl
or an oxide or dioxide thereof each optionally substituted by one
fluoro, chloro, trifluoromethyl, methoxy, cyano, nitro or naphthyl
optionally substituted by fluoro, chloro, trifluoromethyl, methoxy,
cyano or nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl;
benzothiazolyl; benzothiadiazolyl; benzotriazolyl; benzoxazolyl;
benzoxazolonyl; indolyl; indanyl optionally substituted by one or two
fluoro, 3-indazolyl optionally substituted by 1-trifluoromethylphenyl;or phthalazinyl; n is 1 or 2; and X and Y together with the phenyl towhich they are attached form quinolyl; 2-hydroxyquinolyl;
benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl; indazolyl;
2-hydroxyindazolyl; indolyl; spiro; oxindolyl optionally substituted by
one to three of (C.sub.1-C.sub.3) alkyl, or one of chloro, fluoro or
phenyl, said phenyl optionally substituted by one chloro or fluoro;
benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl;
2-aminobenzoxazolinyl; benzothiazolonyl; bezoimidazolonyl; or
benzotriazolyl.
6. The method of claim 5, for stabilizing mood.
April 2022

24
USPATFULL
7. The method of claim 5, for preventing relapse into a bipolar episode.
8. The method of any preceding claim wherein the compound isziprasidone.
9. The method of claim 1, 2, or 5 wherein the compound is ziprasidone
and is administered in dosages of about 0.5 mg to about 500 mg per day.
10. The method of claim 1, 2, or 5 wherein the compound is ziprasidone
and the administration is oral.
11. The method of claim 1, 2, or 5 wherein the compound is ziprasidone
and the administration is parenteral.
12. The method of claim 1, 2, or 5 wherein the treatments effectimprovement in the mammal within about 96 hours after administrating thecompound.
13. The method of claim 1, 2, or 5 wherein the treatments effectimprovement in the mammal within about 24 to about 96 hours afteradministering the compound.

DISPLAY BIB.EX
ANSWER 1 OF 1

USPATFULL on STN-- Original Publication -AN
TIIN(APPLICATION - A1)

2005:44303 USPATFULL Full-text
Treatment of bipolar disorders and associated symptoms
Romano, Steven Joseph, New York, NY, UNITED STATES
Giller, Earl L., Madison, CT, UNITED STATESHarrigan, Edmund P., Old Lyme, CT, UNITED STATES
Seeger, Thomas F., Mystic, CT, UNITED STATESPA
Pfizer Inc (U.S. corporation)PI
US 20050038036
A1 20050217
AI
US 2004-843915
A1 20040512 (10)PRAI
US 2003-471450P
20030516 (60)DT
UtilityFS
APPLICATIONLREPPFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
10017-5612
CLMN
Number of Claims: 13
ECL
Exemplary Claim: 1
DRWN
No Drawings
LN.CNT 972
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

April 2022

25
USPATFULLDISPLAY SPPL1ANSWER 1 OF 1

USPATFULL on STN

AN
2019:273623 USPATFULL Full-text
TI
Soybean variety 5PCDJ10
IN
Owen, Philip A., Baldwin, IL, UNITED STATESPAMONSANTO TECHNOLOGY LLC, St. Louis, MO, UNITED STATES (U.S. corporation)PI
US 10368520
B1 20190806
AI
US 2018-15988342
20180524 (15)DT
UtilityFS
GRANTED
LN.CNT 2255
CPC
CPCI
A01H0005-10 [I]; A01H0006-542 [I]
IPC
IPCI
A01H0005-10 [I]; A01H0006-54 [I]IPCR
A01H0005-10 [I]; A01H0006-54 [I]CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PPAK
100-47-0D, Benzonitrile, Pg 20
290-87-9D, Triazine, Pg 20
30581-70-5D, Cyclohexanedione, Pg 2035724-27-7D, Pg 20
38669-41-9D, Phenoxypropionic acid, Pg 20
1071-83-6, Glyphosate, Pg 20
1689-84-5, Bromoxynil, Pg 20
1918-00-9, Dicamba, Pg 20
51276-47-2, Glufosinate, Pg 20

In North America
CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.
CAS Customer Center:Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)Fax:
614-447-3751
Email:
help@cas.org
Internet: www.cas.org

In Europe
FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax:+49-7247-808-259
Email:
helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan
JAICI (Japan Association forInternational Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)
Fax:+81-3-5978-3600
Email:
support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp

April 2022